Connectivity between laboratory instruments is crucial for capturing large quantities of multimodal data generated during the drug discovery and development process. With the launch of its newest product, Luma Lab Connect, scientific software provider Dotmatics aims to help drug developers extract data from all of their instruments in a centralized and standardized manner for downstream analysis and interpretation.  

A primary benefit of Luma Lab Connect is its ability to automate data flow from lab instruments in real-time in a way that protects the integrity and reliability of experimental results. With Luma Lab Connect, instrument data is piped seamlessly up to Dotmatics’ Luma cloud, a low-code software-as-a-service platform that the company launched in October 2023. It includes tools for structuring lab information in a usable way for artificial intelligence and machine learning-based algorithms. 

Also available are tools for extracting descriptive metadata and harmonizing instrument data with other information from other sources for a more fine-grained analysis. There’s also an option for users to run external analysis tools on their data using open application programming interfaces supplied by Dotmatics.

“Dotmatics is helping labs unlock the value of their data by providing a unified, low-code solution for instrument connectivity, data harmonization, and modeling,” said Dotmatics’ CEO Thomas Swalla. “In the coming years, the companies that own the cleanest, AI-ready data will find the most success pursuing ground-breaking discoveries. Our customers who have adopted Luma Lab Connect are finding immense value from their instrument data, simplifying workflows, and accelerating scientific discovery.”

Dotmatics is already seeing interest in Luma Lab Connect for various drug discovery applications including flow cytometry, screening, and cell line development. Kalim Saliba, chief product officer at Dotmatics, noted that the product is already in use at several large pharmaceutical companies with “hundreds of users live, processing 10s of terabytes of data each day across more than 40 supported formats, covering thousands of instruments.”

In January, Dotmatics announced its acquisition of M-Star, a computational fluid dynamics software company, and stated that the deal would open up opportunities for innovation in bioprocessing including the manufacturing of cell and gene therapies. 

Previous articlePsychosis Development Linked to Brain’s Filter/Predictor Mechanisms
Next articleAI Screening of Pediatric Cancers Improves Treatment Outcomes